請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/32958
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 季昭華 | |
dc.contributor.author | Chieh-Han Yang | en |
dc.contributor.author | 楊杰翰 | zh_TW |
dc.date.accessioned | 2021-06-13T04:20:11Z | - |
dc.date.available | 2008-07-27 | |
dc.date.copyright | 2006-07-27 | |
dc.date.issued | 2006 | |
dc.date.submitted | 2006-07-22 | |
dc.identifier.citation | 1. Coley, W. B. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res: 3-11, 1991.
2. Wiemann, B. and Starnes, C. O. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther, 64: 529-564, 1994. 3. Weiner, G. J. The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides. J Leukoc Biol, 68: 455-463, 2000. 4. Liu, H. M., Newbrough, S. E., Bhatia, S. K., Dahle, C. E., Krieg, A. M., and Weiner, G. J. Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor. Blood, 92: 3730-3736, 1998. 5. Krieg, A. M., Yi, A. K., Matson, S., Waldschmidt, T. J., Bishop, G. A., Teasdale, R., Koretzky, G. A., and Klinman, D. M. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature, 374: 546-549, 1995. 6. Krieg, A. M., Wu, T., Weeratna, R., Efler, S. M., Love-Homan, L., Yang, L., Yi, A. K., Short, D., and Davis, H. L. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci U S A, 95: 12631-12636, 1998. 7. Ballas, Z. K., Krieg, A. M., Warren, T., Rasmussen, W., Davis, H. L., Waldschmidt, M., and Weiner, G. J. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J Immunol, 167: 4878-4886, 2001. 8. Klinman, D. M., Yi, A. K., Beaucage, S. L., Conover, J., and Krieg, A. M. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci U S A, 93: 2879-2883, 1996. 9. Yamamoto, S., Yamamoto, T., Kataoka, T., Kuramoto, E., Yano, O., and Tokunaga, T. Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN [correction of INF] and augment IFN-mediated [correction of INF] natural killer activity. J Immunol, 148: 4072-4076, 1992. 10. Cardon, L. R., Burge, C., Clayton, D. A., and Karlin, S. Pervasive CpG suppression in animal mitochondrial genomes. Proc Natl Acad Sci U S A, 91: 3799-3803, 1994. 11. Razin, A. and Friedman, J. DNA methylation and its possible biological roles. Prog Nucleic Acid Res Mol Biol, 25: 33-52, 1981. 12. Takeshita, F., Leifer, C. A., Gursel, I., Ishii, K. J., Takeshita, S., Gursel, M., and Klinman, D. M. Cutting edge: Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J Immunol, 167: 3555-3558, 2001. 13. Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., and Akira, S. A Toll-like receptor recognizes bacterial DNA. Nature, 408: 740-745, 2000. 14. Takeshita, F. and Klinman, D. M. CpG ODN-mediated regulation of IL-12 p40 transcription. Eur J Immunol, 30: 1967-1976, 2000. 15. Takeshita, F., Ishii, K. J., Ueda, A., Ishigatsubo, Y., and Klinman, D. M. Positive and negative regulatory elements contribute to CpG oligonucleotide-mediated regulation of human IL-6 gene expression. Eur J Immunol, 30: 108-116, 2000. 16. Yamamoto, M., Sato, S., Mori, K., Hoshino, K., Takeuchi, O., Takeda, K., and Akira, S. Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J Immunol, 169: 6668-6672, 2002. 17. Hacker, H., Vabulas, R. M., Takeuchi, O., Hoshino, K., Akira, S., and Wagner, H. Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6. J Exp Med, 192: 595-600, 2000. 18. Klinman, D. M. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol, 4: 249-258, 2004. 19. Rankin, R., Pontarollo, R., Ioannou, X., Krieg, A. M., Hecker, R., Babiuk, L. A., and van Drunen Littel-van den Hurk, S. CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense Nucleic Acid Drug Dev, 11: 333-340, 2001. 20. Messina, J. P., Gilkeson, G. S., and Pisetsky, D. S. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. J Immunol, 147: 1759-1764, 1991. 21. Chu, R. S., Targoni, O. S., Krieg, A. M., Lehmann, P. V., and Harding, C. V. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med, 186: 1623-1631, 1997. 22. Roman, M., Martin-Orozco, E., Goodman, J. S., Nguyen, M. D., Sato, Y., Ronaghy, A., Kornbluth, R. S., Richman, D. D., Carson, D. A., and Raz, E. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med, 3: 849-854, 1997. 23. Hartmann, G., Weiner, G. J., and Krieg, A. M. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci U S A, 96: 9305-9310, 1999. 24. Yamamoto, S., Yamamoto, T., Shimada, S., Kuramoto, E., Yano, O., Kataoka, T., and Tokunaga, T. DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. Microbiol Immunol, 36: 983-997, 1992. 25. Ballas, Z. K., Rasmussen, W. L., and Krieg, A. M. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol, 157: 1840-1845, 1996. 26. Kline, J. N., Waldschmidt, T. J., Businga, T. R., Lemish, J. E., Weinstock, J. V., Thorne, P. S., and Krieg, A. M. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J Immunol, 160: 2555-2559, 1998. 27. Broide, D., Schwarze, J., Tighe, H., Gifford, T., Nguyen, M. D., Malek, S., Van Uden, J., Martin-Orozco, E., Gelfand, E. W., and Raz, E. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. J Immunol, 161: 7054-7062, 1998. 28. Krieg, A. M., Hartmann, G., and Yi, A. K. Mechanism of action of CpG DNA. Curr Top Microbiol Immunol, 247: 1-21, 2000. 29. Davila, E. and Celis, E. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity. J Immunol, 165: 539-547, 2000. 30. Ben-Efraim, S. One hundred years of cancer immunotherapy: a critical appraisal. Tumour Biol, 20: 1-24, 1999. 31. Whiteside, T. L., Vujanovic, N. L., and Herberman, R. B. Natural killer cells and tumor therapy. Curr Top Microbiol Immunol, 230: 221-244, 1998. 32. Carpentier, A. F., Chen, L., Maltonti, F., and Delattre, J. Y. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res, 59: 5429-5432, 1999. 33. Carpentier, A. F., Xie, J., Mokhtari, K., and Delattre, J. Y. Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin Cancer Res, 6: 2469-2473, 2000. 34. Carpentier, A. F., Auf, G., and Delattre, J. Y. CpG-oligonucleotides for cancer immunotherapy : review of the literature and potential applications in malignant glioma. Front Biosci, 8: e115-127, 2003. 35. Jahrsdorfer, B., Wooldridge, J. E., Blackwell, S. E., Taylor, C. M., Griffith, T. S., Link, B. K., and Weiner, G. J. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. J Leukoc Biol, 77: 378-387, 2005. 36. Sharma, S., Karakousis, C. P., Takita, H., Shin, K., and Brooks, S. P. Intra-tumoral injection of CpG results in the inhibition of tumor growth in murine Colon-26 and B-16 tumors. Biotechnol Lett, 25: 149-153, 2003. 37. Meng, Y., Carpentier, A. F., Chen, L., Boisserie, G., Simon, J. M., Mazeron, J. J., and Delattre, J. Y. Successful combination of local CpG-ODN and radiotherapy in malignant glioma. Int J Cancer, 116: 992-997, 2005. 38. Mason, K. A., Ariga, H., Neal, R., Valdecanas, D., Hunter, N., Krieg, A. M., Whisnant, J. K., and Milas, L. Targeting Toll-like Receptor 9 with CpG Oligodeoxynucleotides Enhances Tumor Response to Fractionated Radiotherapy. Clin Cancer Res, 11: 361-369, 2005. 39. Ross, J. S., Schenkein, D. P., Pietrusko, R., Rolfe, M., Linette, G. P., Stec, J., Stagliano, N. E., Ginsburg, G. S., Symmans, W. F., Pusztai, L., and Hortobagyi, G. N. Targeted therapies for cancer 2004. Am J Clin Pathol, 122: 598-609, 2004. 40. Kim, J. A. Targeted therapies for the treatment of cancer. Am J Surg, 186: 264-268, 2003. 41. Klapper, L. N., Kirschbaum, M. H., Sela, M., and Yarden, Y. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res, 77: 25-79, 2000. 42. Salomon, D. S., Brandt, R., Ciardiello, F., and Normanno, N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol, 19: 183-232, 1995. 43. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235: 177-182, 1987. 44. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., and et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244: 707-712, 1989. 45. Eccles, S. A. The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neoplasia, 6: 393-406, 2001. 46. Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., and Shepard, H. M. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A, 89: 4285-4289, 1992. 47. Shepard, H. M., Lewis, G. D., Sarup, J. C., Fendly, B. M., Maneval, D., Mordenti, J., Figari, I., Kotts, C. E., Palladino, M. A., Jr., Ullrich, A., and et al. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J Clin Immunol, 11: 117-127, 1991. 48. Baselga, J., Norton, L., Albanell, J., Kim, Y. M., and Mendelsohn, J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res, 58: 2825-2831, 1998. 49. Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., Rosen, P. P., Twaddell, T., Henderson, I. C., and Norton, L. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol, 14: 737-744, 1996. 50. Emens, L. A. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer. Am J Ther, 12: 243-253, 2005. 51. Arteaga, C. L. Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer. Breast Cancer Res, 5: 96-100, 2003. 52. Lee, S., Yang, W., Lan, K. H., Sellappan, S., Klos, K., Hortobagyi, G., Hung, M. C., and Yu, D. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. Cancer Res, 62: 5703-5710, 2002. 53. Pietras, R. J., Poen, J. C., Gallardo, D., Wongvipat, P. N., Lee, H. J., and Slamon, D. J. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res, 59: 1347-1355, 1999. 54. Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D., and Jain, R. K. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature, 416: 279-280, 2002. 55. Clynes, R. A., Towers, T. L., Presta, L. G., and Ravetch, J. V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med, 6: 443-446, 2000. 56. Kono, K., Sato, E., Naganuma, H., Takahashi, A., Mimura, K., Nukui, H., and Fujii, H. Trastuzumab (Herceptin) enhances class I-restricted antigen presentation recognized by HER-2/neu-specific T cytotoxic lymphocytes. Clin Cancer Res, 10: 2538-2544, 2004. 57. Liang, K., Lu, Y., Jin, W., Ang, K. K., Milas, L., and Fan, Z. Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther, 2: 1113-1120, 2003. 58. Sato, S., Kajiyama, Y., Sugano, M., Iwanuma, Y., Sonoue, H., Matsumoto, T., Sasai, K., and Tsurumaru, M. Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/neu oncoprotein. Int J Radiat Oncol Biol Phys, 61: 203-211, 2005. 59. Miller, G. M., Andres, M. L., and Gridley, D. S. NK cell depletion results in accelerated tumor growth and attenuates the antitumor effect of total body irradiation. Int J Oncol, 23: 1585-1592, 2003. 60. Roda, J. M., Parihar, R., and Carson, W. E., 3rd CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells. J Immunol, 175: 1619-1627, 2005. 61. Makino, M., Shoji, H., Takemoto, D., Honboh, T., Nakamura, S., Kurayoshi, K., and Kaibara, N. Comparative study between daily and 5-days-a-week administration of oral 5-fluorouracil chemotherapy in mice: determining the superior regimen. Cancer Chemother Pharmacol, 48: 370-374, 2001. 62. Okunieff, P., Morgan, D., Niemierko, A., and Suit, H. D. Radiation dose-response of human tumors. Int J Radiat Oncol Biol Phys, 32: 1227-1237, 1995. 63. Parihar, R., Dierksheide, J., Hu, Y., and Carson, W. E. IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. J Clin Invest, 110: 983-992, 2002. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/32958 | - |
dc.description.abstract | 本實驗假設將單株抗體和CpG ODN結合,活化自然殺手細胞,進而增加放射線治療的成效。這樣的假設還沒有被人證明過。本研究的目的為探討以CpG寡核酸結合HER2/neu單株抗體Herceptin增強放射線治療的效果,實驗內容包括小白鼠動物實驗以及細胞實驗,所使用的腫瘤細胞株為CT26HER2/neu,這是一種從BALB/c小鼠為來源的大腸癌細胞,且被轉殖過因而可以大量的表現人類的HER2/neu。當腫瘤在BALB/c小鼠的皮下生長達到4mm的直徑時,每天給予腫瘤內注射CpG ODN 100μ以及腹腔注射Herceptin 200μg,連續三天,第四天再讓小鼠接受局部不同劑量的放射線治療,之後持續的記錄腫瘤的大小以及小鼠的存活比例,並研究放射線治療的半存活劑量TCD50以及觀察再次注射腫瘤的生長情形。至於體外的細胞實驗則藉由在照射放射線之前將CT26HER2/neu以及從小鼠脾臟取出的脾臟細胞共同培養,分別加入或不加入CpG ODN以及Herceptin,觀察其細胞激素的變化以及放射線對腫瘤細胞的傷害的改變。發現在照射放射線之前給予CpG以及Herceptin比單獨給予的組別更能夠延遲腫瘤生長的速度並且增長小鼠存活的時間。細胞實驗也證明了同時存在CpG以及Herceptin能夠更加的刺激小鼠脾臟細胞分泌IFN-r並且使腫瘤細胞在照完放射線後有更高比例的細胞死亡。實驗結果證明結合CpG ODN和Herceptin能夠提高CT26HER2/neu對放射線的敏感度,能夠增加放射線治療的功效。 | zh_TW |
dc.description.abstract | We hypothesized that targeted therapy with antibody in combination of CpG oligodeoxynucleotides (ODN) would further activate NK cells and resulte in strong radiosensitization effect. This hypothesis has never been proved. The effects of blocking HER2 by Herceptin in combination of CpG ODN on radiosensitization effect were evaluated in this experiment. A BALB/c murine colon carcinoma line overexpressing human HER2/neu, CT26HER2/neu, was used in our experiment. When tumor reaches 4mm in diameter, CpG ODN 100μ intratumorally and Herceptin 200μg intraperitoneally were injected per mice in consecutive three days. Radiation of 800cGy to tumor was performed on day 4. Tumor growth curve, survival rate, TCD50, and tumor rechallenge were studied. In vitro radiosensitization effects were investigated by coculture with CT26HER2/neu with PBMC with or without CpG and Herceptin before radiation. Cytokine profiles changes were also evaluated. The combination of CpG and Herceptin before radiation retard tumor growth and prolong survival of mice in comparison with CpG only or Herceptin only. The long term tumor control rate was increased. In vitro experiments demonstrated that the combination of CpG and Herceptin stimulate more IFN-r (160pg/ml) than CpG only (130pg/ml) or Herceptin only (27pg/ml) on mice splenocytes, and increase the cell lysis percentage caused by RT (44.7%) compared with CpG only (29.94%). Our study indicated that the combination of CpG ODN and Herceptin sensitize CT26HER2/neu to radiation-induced apoptosis. Co-injection CpG and Herceptin may effectively enhance radiotherapy efficacy. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T04:20:11Z (GMT). No. of bitstreams: 1 ntu-95-R93629031-1.pdf: 933291 bytes, checksum: ecd12ba907ee053a7690d3ec86d02e06 (MD5) Previous issue date: 2006 | en |
dc.description.tableofcontents | 中文摘要…………………………………………………...…………….1
英文摘要……………………………………………………………...….3 緒言………………………………………………………………………4 壹、文獻回顧 第一章CpG oligodeoxynucleotides 第一節 CpG oligodeoxynucleotides的起源………..……….………..5 第二節 CpG oligodeoxynucleotides的機制….…….….………....….6 第三節 CpG oligodeoxynucleotides的應用…….…..………….…...10 第二章 標的治療 (targeted therapy) 第一節 簡介標的治療……………………………………...…….....12 第二節 HER2/neu (erbB2)……………………...………….………..13 第三節 Herceptin…………………………………………….……...14 貳、研究動機………………………………………..…………………..18 參、研究方法與步驟 第一節 實驗動物與腫瘤施打 3.1.1 實驗動物……………………………………...…..…...…19 3.1.2 細胞株……………………………………………………19 3.1.3 細胞培養材料.…………………………………………19 3.1.4 CpG ODNs和抗體………………………………………20 3.1.5 腫瘤施打…………………………………………………20 第二節 實驗動物模型 3.2.1 腫瘤生長曲線……………………………………………21 3.2.2 腫瘤控制機率(tumor control probability)……………….22 3.2.3 放射線照射………………………………………………23 3.2.4 再次接種腫瘤……………………………………………26 第三節 CpG ODN毒性測試……………………………....……..…26 第四節 CpG ODN之放射線敏感性測試……...………..………….27 第五節 小鼠脾臟細胞分泌IFN-r測試 3.5.1 小鼠脾臟細胞分離……………………………………..28 3.5.2 細胞激素酵素連結免疫吸附反應....................................29 3.5.3 實驗設計…………………………………………………30 第六節 體外放射線敏感性測試 3.6.1 LDH檢驗套組…………………………………………...30 3.6.2 實驗設計....................………………………...…..…...…33 第七節 統計分析…...………………………..……...………………34 肆、結果 第一節 CpG ODNs對腫瘤細胞的毒殺作用……...…………..……35 第二節 CpG ODNs對於放射線治療的協同作用…………...……..37 第三節 被CpG ODNs刺激過的小鼠脾臟細胞可以增加Herceptin鍵結的腫瘤細胞的放射線敏感性……….…………….…..39 第四節 當遇到被Herceptin鍵結的腫瘤細胞時,CpG 1826可以增加小鼠脾臟細胞分泌IFN-r………………………………...41 第五節 結合CpG ODNs和放射線治療時CpG ODNs施打的時機……………………………………………………………44 第六節 結合CpG ODNs和Herceptin可以增加放射線治療的功效……………………………………………………………46 第七節 單純使用CpG ODNs治療和結合CpG ODNs以及Herceptin治療對於腫瘤控制機率的比較…………..………………..50 第八節 再次接種腫瘤比較小鼠的免疫保護力……………………52 伍、討論……………………………….………………...……………..54 陸、結論…………....……………………………............……………..59 柒、參考文獻……………………………………............……………..60 | |
dc.language.iso | zh-TW | |
dc.title | 以CpG ODNs (CpG寡核酸)結合HER2/neu單株抗體(Herceptin)增強放射線治療的效果 | zh_TW |
dc.title | Synergistic Radiosensitization Effect of Combination of CpG ODNs and Herceptin | en |
dc.type | Thesis | |
dc.date.schoolyear | 94-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 季匡華 | |
dc.contributor.oralexamcommittee | 吳應寧,黃正仲 | |
dc.subject.keyword | 放射線,CpG寡核酸,單株抗體,腫瘤治療, | zh_TW |
dc.subject.keyword | radiation,CpG ODNs,Herceptin,tumor therapy, | en |
dc.relation.page | 67 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2006-07-24 | |
dc.contributor.author-college | 生物資源暨農學院 | zh_TW |
dc.contributor.author-dept | 獸醫學研究所 | zh_TW |
顯示於系所單位: | 獸醫學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-95-1.pdf 目前未授權公開取用 | 911.42 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。